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Abstract 
Little is known about the possible oncogenic roles of genes encoding for the phosphatidylinositol 
4-kinases, a family of enzymes that regulate an early step in phosphoinositide signalling. To address 
this issue, the mutational status of all four human phosphatidylinositol 4-kinases genes was ana-
lyzed across 852 breast cancer samples using the COSMIC data resource. Point mutations in the 
phosphatidylinositol 4-kinase genes were uncommon and appeared in less than 1% of the patient 
samples however, 62% of the tumours had increases in gene copy number for PI4KB which encodes 
the phosphatidylinositol 4-kinase IIIbeta isozyme. Extending this analysis to subsequent enzymes in 
the phosphoinositide signalling cascades revealed that the only PIP5K1A, PI3KC2B and AKT3 genes 
exhibited similar patterns of gene copy number variation. By comparison, gene copy number in-
creases for established oncogenes such as EGFR and HER2/Neu were only evident in 20% of the 
samples. The PI4KB, PIP5K1A, PI3KC2B and AKT3 genes are related in that they all localize to 
chromosome 1q which is often structurally and numerically abnormal in breast cancer. These 
results demonstrate that a gene quartet encoding a potential phosphoinositide signalling pathway is 
amplified in a subset of breast cancers. 
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Introduction 
The starting point for this study was the in-
creasing number of reports describing possible roles 
for the PtdIns (PtdIns) 4-kinase enzymes in cancer 
[1-11].  PtdIns 4-kinases catalyze the phosphorylation 
of PtdIns on the D4 position to produce PtdIns4P.   
This lipid product can be subsequently utilized by 
downstream phosphoinositide kinases and phospha-
tases to generate lipids such as PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3 which have important signalling and 
trafficking functions. Therefore the synthesis of 
PtdIns4P is necessary for almost all of the cellular 
functions ascribed to the phosphoinositide lipids in-
cluding the regulation of cell proliferation, survival 
and motility. Moreover, phosphoinositide-dependent 
deregulation of these functions is well documented in 
cancer; and this has mainly been attributed to acti-
vating point mutations in genes for particular PtdIns 
3-kinase isoforms such as PIK3CA, or the reduced 
expression of phosphoinositide phosphatases such as 
PTEN. These genetic mutations result in elevated 
concentrations of particular phosphoinositide species 
such as PtdIns(3,4,5)P3 and trigger the activation of  
downstream effecter proteins such as PDK and Akt 
[12, 13]. In addition to activating mutations and gene 
deletions more recent work has indicated that in-
creased levels of individual phosphoinositide metab-
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olizing enzymes such as PIK3CA may be sufficient to 
drive pro-oncogenic signalling [14, 15].   
While there is some evidence that PtdIns 
4-kinase expression is important in breast cancer [1, 3, 
4, 8, 16] the genetic basis for this remains unexplored. 
To address this knowledge gap the mutational status 
of the genes encoding for each PtdIns 4-kinase iso-
zyme was analyzed across 852 breast cancer genomes 
collated in the catalogue of somatic mutations in can-
cer (COSMIC) database. This strategy was then ex-
tended to downstream components of the phospho-
inositide signalling cascades in order to establish if 
any particular enzymatic pathway was upregulated at 
the genomic level. This approach culminated in the 
identification of four genes localized to chromosome 
1q which exhibited similar copy number increases in 
over 60% of the tumour samples analyzed and which 
could potentially constitute a novel pro-oncogenic 
signalling cascade in breast cancer.  
Methods 
Genomic analysis.  The catalogue of somatic 
mutations in cancer (COSMIC) bioinformatics re-
source (http://www.sanger.ac.uk/cosmic) [17, 18] 
established and maintained by Wellcome Trust Sang-
er Institute was used in order to identify changes in a 
panel of genes encoding for enzymes along the 
phosphoinositide signalling pathway. The initial ge-
nomic breast cancer data was derived from 852 indi-
vidual tumour samples collated from two independ-
ent studies - the breast cancer (UK) project and breast 
invasive carcinoma data from the Cancer Genome 
Atlas (USA). For these samples, in the COSMIC V69 
database, gene copy number analysis was via ASCAT 
(Allele-Specific Copy number Analysis of Tumors) 
algorithm software [19] available at 
http://heim.ifi.uio.no/bioinf/Projects/ASCAT. For 
this analysis the average copy number for the genome 
is 1.90 and a reduction in total copy number to a value 
of 1.30 was taken to demarcate a loss. Copy number 
gain was specified when average ploidy ≥ 1.8 and 
gene copy number ≥ 3.  For a more stringent assess-
ment of copy number amplification taking into ac-
count changes arising from changes to ploidy, the 
ASCAT criteria used in COSMIC V70 were employed.  
In this analysis copy number gain is defined as either 
average genome ploidy <= 2.7 and total gene copy 
number >= 5 or in the case of genome duplication 
average genome ploidy > 2.7 and gene copy number 
>= 9. Note that the copy number data calculated from 
COSMIC V70 was from an increased cohort of 939 
patient samples. 
Protein expression analysis using a web-based 
database.  The Human Protein Atlas [20, 21] 
(www.proteinatlas.org) on-line resource was em-
ployed to investigate the expression of candidate 
proteins identified from the genomic analyses. These 
immunohistochemical data were obtained from du-
plicate, paraffin-embedded 1 mm cores from patient 
surgical samples arranged on tissue microarrays. A 
full description of the procedures and antibodies used 
in these studies is available on the Human protein 
Atlas web-site. 
Results & Discussion 
PtdIns 4-kinases catalyze the phosphorylation of 
PtdIns to generate PtdIns4P and this is the first com-
mitted energy consuming step in the pathway that 
produces the signalling molecules PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3. The initial aim of this study was to 
ascertain if any PtdIns 4-kinase gene was mutated in 
breast cancer. The COSMIC database which collates 
genomic sequencing results from different studies 
was searched, and of the four mammalian PtdIns 
4-kinases only the PI4KB gene which encodes PtdIns 
4-kinase IIIβ was found to be commonly mutated 
(Figure 1). In over 60% of the samples surveyed there 
was an increase in PI4KB gene copy number. Moreo-
ver, there were concomitant decreases in gene copy 
number for the other PtdIns 4-kinase genes indicating 
that in breast cancer PI4KB is the dominant PtdIns 
4-kinase.  Across all four human PtdIns 4-kinase genes 
less than 1% exhibited point mutations indicating that 
this type of genetic alteration was unlikely to signifi-
cantly contribute to breast cancer tumourigenesis.  
This data mining strategy was extended to en-
compass copy number variation for genes encoding 
proteins involved in subsequent steps in phospho-
inositide signalling (Figure 2).  Investigating the copy 
number status of genes for the PtdIns4P 5-kinases 
which produce PtdIns(4,5)P2 by D5 phosphorylation 
of PtdIns4P and the PtdIns5P 4-kinases which pro-
duce the same lipid product via phosphorylation of 
PtdIns5P on the D4 position, revealed that of the five 
candidate genes examined, only PI4P5K1A demon-
strated increased copy number  in breast cancer.  A 
similar approach focused on the phosphoinositide 
3-kinase gene family, identified a substantial gene 
copy number increase for PIK3C2B which encodes a 
PtdIns4P 3-kinase. To complete this analysis the status 
of all three human AKT genes was assessed and copy 
number gains were most noteworthy for the gene 
encoding the Akt3 isoform and again this was in over 
60% of the patient samples. Hence in the majority of 
the breast cancer cases represented on the COSMIC 
database there was an elevation in gene copy number 
for PI4KB, PIP5K1A, PIK3C2B and AKT3. Interesting-
ly, this phosphoinositide gene quartet maps to chro-
mosome 1q – a chromosome which is numerically 
abnormal in up to 50-60% of breast cancers [22-25]. 
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Comparisons with established oncogenes (Figure 3) 
indicated that the copy number increase for PI4KB 
was 2-3 fold higher than for tumour promoter genes 
such as EGFR and HER2/NEU. Furthermore the mag-
nitude of PI4KB copy number amplification mirrored 
the scale of copy number loss for tumour suppressor 
genes such as TP53 and PTEN.  
 
 
Figure 1. Analysis of mutations in the genes encoding for the four human PtdIns 
4-kinases in the 852 breast cancer samples collated in the COSMIC database. (a) Over 
60% of breast cancer samples have increased copy numbers of the PI4KB gene. (b) 
Analysis of PtdIns 4-kinase gene copy number loss and (c) frequency of point muta-
tions in the same breast cancer samples. 
 
To further analyse the degree to which these 
genes were amplified in each breast cancer case, the 
copy number status of each gene was investigated in 
individual patient samples (Figure 4). These results 
showed that gene copy number amplification for this 
pathway ranged from 3 -16 additional copies but that 
for most tumours the range was 3 - 6 extra copies. 
Since gene copy number increases can arise from ei-
ther an increase in ploidy - a common event associ-
ated with multinucleation in many cancers, or from 
numerical increases in specific chromosomes, a more 
stringent algorithm was employed in order to mini-
mize the contribution of copy number variation 
caused solely by changes to complete genome dupli-
cation. Application of these more rigorous thresholds 
revealed that all four genes of interest were amplified 
in approximately 10% of breast cancer samples (10% 
for PI4KB, 11.4% for AKT3, 11.3% for PIK3C2B and 
10.2% for PIP5K1A). These values are consistent with 
copy number co-amplification arising from numerical 
increases to chromosome 1q and not solely by mitotic 
defects leading to genome duplication.  
 
 
Figure 2. Copy number increases in genes encoding for enzymes downstream of the 
PtdIns 4-kinases in the COSMIC breast cancer database. The chromosomal localiza-
tion of each gene is given in brackets. 
 
 
Figure 3. Comparison of the changes in gene copy number variation in PI4KB with 
more established oncogenes and tumour suppressor genes in breast cancer. 
 
 
Figure 4. Histogram demonstrating the distribution of copy number increases in 
individual breast tumours for each of the amplified phosphoinositide pathway genes 
identified. 
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To further probe the specificity of this finding for 
the quartet of phosphoinositide metabolizing genes, 
the copy number status of functionally unconnected 
and randomly chosen genes mapping elsewhere to 
chromosome 1 were assessed. The genes used in this 
test were CRP banding at 1q23.2 encoding C-reactive 
protein, LMNA at 1q22 which encodes nuclear lami-
nar protein lamin A/C and PSEN2 at 1q42.13 which 
encodes presenilin 2, a protein which is sometimes 
mutated in inherited forms of Alzheimer's disease.  
The level of high copy number amplification for all 
three of these genes was similar to that observed for 
the quartet of phosphoinositide signalling enzymes at 
8.5% for CRP, 7.88% for LMNA and 10.33% for PSEN2. 
These results indicate that the genes in question are 
amplified due to their co-localization to chromosome 
1q and furthermore that this effect is not specific for 
phosphoinositide pathway genes.   
To ascertain whether amplification of this gene 
quartet occurs in cancers affecting tissues other than 
breast, an assessment of copy number variation across 
multiple tissues was performed (Figure 5). From this 
analysis it was clear that co-amplification of 
PI4KB/PIPK1A/AKT3/PIK3C2B was most pronounced 
for breast carcinoma but also occurred in about 5% of 
endometrial cancers, lung adenocarcinomas and 
ovarian cancer. Mutations in these four genes were 
also found more rarely in less than 1% of cancers af-
fecting the large intestine and kidney.  These results 
demonstrate that amplification of this gene set is most 
commonly detected in invasive breast carcinoma but 
can also be found in other malignancies but at much 
lower frequencies.  
One possible selective pressure to drive ampli-
fication of PtdIns4P and PtdIns(4,5)P2 generation 
could be the co-presence of constitutively active on-
cogenic PIK3CA requiring an increased input of 
phosphoinositide substrate to produce 
PtdIns(3,4,5)P3.  Moreover, activating point mutations 
of PIK3CA have previously been reported in breast 
cancer and this therefore prompted an assessment of 
the frequency and types of PIK3CA point mutations in 
each of the patient samples with PI4KB amplification. 
This analysis revealed that activating PIK3CA amino 
acid point mutations were present in 22/93 (23.7%) of 
the high copy number PI4KB samples which was 
similar to 26.44% frequency for point mutations in this 
gene for all samples in the database. The vast majority 
of PIK3CA point mutations in high PI4KB samples 
were H1074R substitutions (13/24), followed by 
E545K (6/24), G118D (1/24) and C240R (1/24) acti-
vating mutations.  Inactivating PTEN mutations were 
rarer and found in just 3 of the high PI4KB tumours, 
and in only one instance was this co-incident with a 
PIK3CA activating point mutation. Hence it is possible 
that about a quarter of the samples in question had a 
potential selective pressure for increased PtdIns 
4-kinase and PtdIns4P 5-kinase activity to supply 
phosphoinositide substrate to a constitutively active 
PIK3CA however, this was not the case for the major-
ity of the tumours with amplified PI4KB. 
Finally, the Human Protein Atlas [20, 21] 
(www.proteinatlas.org) was surveyed to search if 
there was any evidence for upregulated expression of 
the enzyme products of the four identified genes in 
breast cancer tissues.  In normal breast tissue (Figure 
6), the strongest intensity of immunohistochemical 
staining for PtdIns 4-kinase IIIβ, PtdIns4P 5-Kinase 
1α, Akt3 and phosphoinositide 3-kinase C2β was in 
the ductal tissue. Increased expression of all four 
proteins was observed in ductal carcinomas and this 
was most pronounced for the PtdIns 4-kinase IIIβ and 
phosphoinositide 3-kinase C2β proteins. For the 
eleven antibody-stained breast cancer tumour sam-
ples in the human protein atlas, the intensity of an-
ti-PtdIns 4-kinase IIIβ  staining was classified as 
moderate or strong in 8/11 cases. Similarly for the 
PIK3C2B gene product, 8/11 patient samples exhib-
ited strong expression.  Immunohistochemical stain-
ing for PIP5K1A was less strong with only low level 
immunoreactivity detected in 7/11 tumours. This 
mirrored the immunohistochemical data for Akt3 
where 8/12 samples were determined to have low 
expression of this protein and only one sample exhib-
ited moderate Akt3 overexpression. However, while 
these immunohistochemical results partly support the 
genomic data they need to be treated with caution as 
they derive from a much lower number of patient 
samples and from tumours where the chromosome 1q 
status was not known. 
In conclusion, the genomic analyses presented 
here reveal that a significant proportion of breast 
cancer tumours possess gene copy number increases 
for a quartet of enzymes along a D4 phosphoinositide 
signalling cascade.  The exact functional relationship 
between gene copy number variation and disease is 
still being established [26-28] but increased gene 
dosage and downstream protein expression are very 
likely to define molecular gene expression signatures 
in several cancer subtypes [28].  Since the four identi-
fied phosphoinositide pathway genes are all located 
on chromosome 1q it is likely that their increased copy 
number variation reflects the frequent chromosome 1 
abnormalities that have been established for several 
years in breast cancer [22, 24, 29, 30]. Furthermore, 
amplification of this specific gene set has the potential 
to lead to enhanced phosphoinositide synthesis po-
tentially giving rise to augmented cell proliferation 
and motility [31-33] and hence a more aggressive tu-
mour [1, 34-44]. These insights may have implications 
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for the use of small molecule inhibitors of phospho-
inositide signalling that are currently in development 
since with the possible exception of Akt3 [41], none of 
these four enzymes has previously been considered as 
a high profile chemotherapeutic target [12, 45, 46]. 
Moreover, the high degree of functional redundancy 
for enzymes involved in phosphoinositide synthesis 
[47, 48] combined with the possible amplification of 
the particular phosphoinositide signalling pathway 
identified here, has the potential to give rise to en-
hanced chemoresistance and survival adaptation. 
Noteworthy in this context is the recent finding that 
overexpression of PI4P 5-kinase 1α in prostate cancer 
cells leads to augmented Akt activation, enhanced 
invasiveness and a poor prognosis for this disease 
[49].  Therefore, structural alterations and duplica-
tions of chromosome 1q which are common in breast 
cancer, may lead to aberrant phosphoinositide supply 
to key oncogenic driver pathways. 
 
 
Figure 5. Prevalence of high level gene copy number increases for PI4KB, AKT3, PIP5K1A and PIK3C2B in a range of cancers affecting different tissues. The data were derived from 
the COSMIC V70.  The number of patient samples used for each analysis is given in brackets after the tissue name. Breast refers to invasive breast carcinoma, ovary to ovarian 
serous cyst adenocarcinoma, kidney to clear cell carcinoma, endometrium to uterine corpus endometrial cancer, large intestine to colon adenocarcinoma and lung to lung 
adenocarcinoma.  
 
Figure 6. Expression of phosphoinositide signalling proteins in normal breast tissue and in ductal carcinoma. Images were obtained by immunohistochemical staining of 
paraffin-embedded tissue samples using isoform-specific antibodies directed against the protein products of PI4KB, PIP5K1A, PIK3C2B and AKT3.  Antibody binding appears as 
brown/black staining on a background of blue hematoxylin counterstain. All images are from the Human Protein Atlas. 
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